Cardiovascular diseases in patients with high levels of plasma high density lipoprotein: Association with increased plasma oxidative state

Israel Medical Association Journal

Volumn 5, Issue 10, 2003, Pages 702-705

  Shimoni, Nir ^a   Kaplan, Marielle ^b   Keidar, Shlomo ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

High density lipoprotein; Lipid peroxidation; Vascular diseases

Indexed keywords

CHOLESTEROL; HEALTH RISKS; LIPIDS; PATIENT MONITORING; PROTEINS;

CARDIOVASCULAR DISEASES;

DISEASES;

ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FACTORIAL ANALYSIS; HEALTH STATUS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIPID PEROXIDATION; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING HABIT; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

AGED; ARYLDIALKYLPHOSPHATASE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; MIDDLE AGED; RISK FACTORS;

EID: 0242721124     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Castelli WP, Garisson RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.
2. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming. Part I. Circulation 2001;104(19):2376-83.
3. Navab M, Van Lenten BJ, Reddy ST, Fogelman AM. High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation 2001;104(20):2386-7.
4. Larsen BA, Nordestgaard BG, Steffensen R, Jensen G, Hansen AT. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000;101:1907-12.
5. Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, Stefanick ML. Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J 2000;139:288-96.
6. Drexel H, Amann FW, Rentsch K, et al. Relation of the level of high-density lipoprotein subfractions to the presence and extent of coronary heart disease. Am J Cardiol 1992;70:436-40.
7. Hamad A, Salameh M, Mahmoud H, Singh J, Zaghmout M, Ward L. Relation of high levels of high-density lipoprotein cholesterol to coronary artery disease and systemic hypertension. Am J Cardiol 2001;88:899-901.
8. Ross R. The pathogenesis of atherogenesis. An update. N Engl J Med 1986;314:498-500.
9. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms: Oxidation, inflammation and genetics. Circulation 1995;91:2488-96.
10. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
11. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
12. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different than that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q R Arterioscler Thromb Vasc Biol 1998;18:1617-24.
13. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;30:2510-17.
14. Harjai KJ. Potential new cardiovascular risk factors: Left ventricular hypertrophy, homocysteine, lipoprotein (a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999;131:376-86.
15. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercial reagent. J Lipid Res 1989;30:627-30.
16. Miller NJ, Rice-Evans C, Davies MJ, et al. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407-12.
17. Otsuji S, Shibata H, Umada M. Turbidimetric immunoassay of serum C-reactive protein. Clin Chem 1982;28:2121-4.
18. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis 1993;100:1-12.
19. Ubbink JB, Vermaak WJH, Bissbort S. Rapid high performance liquid chromatography assay for total homocysteine levels in human serum. J Chromatogr 1991;565:441-6.
20. Stein Y, Stein O. Atheroprotective mechanisms of HDL. Atherosclerosis 1999;144:285-301.
21. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res 2000;41(9):1481-94.
22. Eckardstein A, Nofer JR, Assman G. High density lipoproteins and arteriosclerosis: Role for cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27.
23. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001;161(3):361-6.
24. Kamel WB. Age-adjusted 7-year total CHD incidence per 1000 by total cholesterol ratio. Am Heart J 1987;114:413-29.
25. Nagano Y, Arai H, Kita T. High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 1991;88(15):6457-61.